Polypharmacy and multiple sclerosis: A population-based study.

ABSTRACT:

Background

Little is known about polypharmacy and multiple sclerosis (MS).

Objectives

To estimate polypharmacy prevalence in a population-based MS cohort and compare persons with/without polypharmacy.

Methods

Using administrative and pharmacy data from Canada, we estimated polypharmacy prevalence (⩾5 concurrent medications for >30 consecutive days) in MS individuals in 2017. We compared the characteristics of persons with/without polypharmacy and described the number of polypharmacy days, the most common medication classes contributing to polypharmacy and hyper-polypharmacy prevalence (⩾10 medications).

Results

Of 14,227 included individuals (75% women), mean age = 55.4 (standard deviation (SD): 13.2) years; 28% (n = 3995) met criteria for polypharmacy (

SUBMITTER: Chertcoff A 

PROVIDER: S-EPMC9896267 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature